What is OurPharma?
OurPharma operates as a specialized provider of high-quality compounded pharmaceuticals, leveraging a state-of-the-art 503B outsourcing facility. The company is dedicated to supplying essential sterile injectables, intravenous fluids, and medication cassettes. Its commitment to quality is reinforced by rigorous FDA-regulated analytics testing. OurPharma's core clientele comprises healthcare organizations that depend on reliable and effective pharmaceutical solutions. The company's focus on transparency and continuous product development aims to address the evolving demands of healthcare providers and patients, positioning it as a key player in the pharmaceutical supply chain.
How much funding has OurPharma raised?
OurPharma has raised a total of $709K across 3 funding rounds:
Debt
$150K
Debt
$309K
Private Equity
$250K
Debt (2020): $150K with participation from PPP
Debt (2021): $309K led by PPP
Private Equity (2025): $250K, investors not publicly disclosed
What's next for OurPharma?
The recent major strategic investment signals a pivotal phase for OurPharma, likely enabling accelerated expansion of its product portfolio and enhancement of its manufacturing capabilities. This capital infusion is expected to bolster its market presence and facilitate deeper penetration into the healthcare sector. Future strategic initiatives may involve further research and development into novel pharmaceutical compounds, as well as potential partnerships to broaden its distribution network. The company's sustained focus on quality and compliance, coupled with this significant financial backing, positions it for continued growth and innovation in the competitive pharmaceutical landscape.
See full OurPharma company page
